Dyslipidaemia and cardiovascular risk in diabetes

Diabetes, Obesity and Metabolism

Volumn 1, Issue 4, 1999, Pages 189-198

  Cullen, Paul ^a,c   Von Eckardstein, Arnold ^a   Souris, Sotiris ^b   Schulte, Helmut ^a   Assmann, Gerd ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Apollonio Hospital   (Greece)

^c Severi Med Laboratories   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERLIPIDEMIAS; MODELS, BIOLOGICAL; RISK FACTORS;

EID: 0033157212     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.1999.00030.x     Document Type: Review

References (73)

1. Wilson PWF, Kannel WB. Epidemiology of hyperglycemia and atherosclerosis. In: Rudermann N, Williamson J, Brownlee M, eds. Hyperglycemia, Diabetes and Vascular Disease. New York: Oxford University Press, 1992: 21-29.
2. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it? Lancet 1997; 350 (Suppl): 4-9.
3. UKPDS Group. UK Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin dependent diabetes mellitus. Ann Intl Med 1996; 124: 136-145.
4. Kannel WB, Wilson PWF. Risk factors that attenuate the female coronary disease advantage. Arch Intl Med 1995; 155: 57-61.
5. Herlitz J, Bang A, Karlson BW. Mortality, place and mode of death and reinfarction during a period of 5 years after acute myocardial infarction in diabetic and non-diabetic patients. Cardiology 1996; 87: 423-428.
6. Miettinen H, Lehto S, Salomaa V et al. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 1998; 21: 69-75.
7. Kubota I, Ito H, Yokoyama K, Yasumura S, Tomoike H. Early mortality after acute myocardial infarction -Observational study in Yamagata. 1993-95. Jap Circ J (English edition) 1998; 62: 414-418.
8. Niakan E, Harati Y, Rolak LA, Comstock JP, Rokey R. Silent myocardial infarction and diabetic cardiovascular autonomic neuropathy. Arch Intl Med 1986; 146: 2229-2230.
9. Chiariello M, Indolfi C, Cotecchia MR, Sifola C, Romano M, Condorelli M. Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic-patients. Am Heart J 1985; 110: 529-534.
10. Abbott RD, Donahue RP, Kannel WB, Wilson PWF. The impact of diabetes on survival following myocardial-infarction in men vs. women. J Am Med Assoc 1988; 260: 3456-3460.
11. Smith JW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54: 718-721.
12. Vacek J. Silent myocardial-infarction in the diabetic population. Am J Med 1984; 76: A59.
13. Melchior T, Kober L, Madsen CR et al. Accelerating impact of diabetes on mortality in the years following an acute myocardial infarction. Diabetologia 1998; 41: 1322.
14. Dullaart RP. Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Neth J Med 1995; 46: 44-54.
15. Winocour PH, Durrington PN, Ishola M, Hillier VF, Anderson DC. The prevalence of hyperlipidaemia and related clinical features in insulin-dependent diabetes mellitus. Quarterly J Med 1989; 70: 265-276.
16. Moore WV, Knapp J, Kauffman RL, Perkins WG. Plasma lipid levels in insulin-dependent diabetes mellitus. Diabetes Care 1979; 2: 31-34.
17. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179-1184.
18. Budde T, Fechtrup C, Bosenberg E et al. Plasma Lp(a) Levels correlate with number, severity, and length-extension of coronary lesions in male-patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterio Thromb 1994; 14: 1730-1736.
19. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-2199.
20. Sandkamp M, Funke H, Schulte H, Köhler E, Assmann G. Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 1990; 36: 20-23.
21. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301: 1248-1251.
22. Austin MA, Sandholzer C, Selby JV, Newman B, Krauss RM, Utermann G. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Human Gen 1992; 51: 829-840.
23. Wade DP, Clarke JG, Lindahl GE et al. Genetic influences on lipoprotein(a) concentration. Biochem Soc Trans 1993; 21: 499-502.
24. Kronenberg F, Kathrein H, Konig P et al. Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease. Arterio Thromb 1994; 14: 1405-1411.
25. Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904-910.
26. Molitch ME, DeFronzo RA, Franz MJ et al. for the American Diabetes Association. Diabetic nephropathy. Diabetes Care 1999; 22 (Suppl): S66-S69.
27. Nelson RG, Bennett PH, Beck GJ et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. New Engl J Med 1996; 335: 1636-1642.
28. World Health Organisation. The World Health Report 1997. Conquering Suffering, Enriching Humanity. Geneva: World Health Organization, 1997.
29. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 1999; 22: S20-S23.
30. Alberti KGMM, Zimmet PZ, for the WHO consultation on diabetes mellitus. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus-Provi-sional report of a WHO consultation. Diabetes Care 1998; 15: 539-553.
31. Keen H. Impact of new criteria for diabetes on pattern of disease. Lancet 1998; 352: 1000-1001.
32. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham study. Am Heart J 1985; 110: 1100-1107.
33. Syvanne M, Taskinen M-R. Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet 1997; 350 (Suppl): 20-23.
34. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.
35. Ruiz J, Blanche H, Cohen N et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart-disease in non-insulin-dependent diabetes mellitus. Proceed Nat Acad Sci USA 1994; 91: 3662-3665.
36. Haffner SM, Stern MP, Hazuda HP, Mitchell BDPJK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? J Am Med Assoc 1990; 63: 2893-2898.
37. Reaven GM. Role ofsulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
38. Williams RR, Hopkins PN, Hunt SC et al. Familial dyslipidaemic hypertension and other multiple metabolic syndromes. Ann Med 1992; 24: 469-475.
39. Frayn KN. Insulin resistance and lipid metabolism. Curr Op Lipidol 1993; 4: 197-204.
40. McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992; 258: 766-770.
41. Boden G, Chen X, Ruiz J, White JV., Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1998; 93: 2438-2446.
42. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20: 614-620.
43. Goldberg RB., Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998; 98: 2513-2519.
44. Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987; 317: 1237-1245.
45. Koskinen P, Manttari M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
46. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998; 339: 229-234.
47. Haffner SM. for the American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 1999; 22 (Suppl): S56-S61.
48. Grundy SM, Bilheimer D, Chait A et al. Summary of the second report of the national-cholesterol-education-program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015-3023.
49. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (The CURVES study). Am J Cardiol 1998; 81: 582-587.
50. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998; 81: B66-B69.
51. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterio Thromb Vase Biol 1995; 15: 678-682.
52. Pfeffer MA, Sacks FM, Moye LA et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995; 76: 98C-106C.
53. Dart A, Jerums G, Nicholson G et al. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia. Am J Caidiol 1997; 80: 39-44.
54. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4s). Lancet 1994; 344: 1383-1389.
55. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995; 333: 1301-1307.
56. Bakker-Arkema RG, Davidson MH, Goldstein RJ et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 1996; 275: 128-133.
57. Stein EA, Davidson MH, Dujovne CA et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia. J Cardiovasc Pharmacol Therap 1996; 1: 107-116.
58. Barasch E, Benderly M, Graff E et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients: the bezafibrate infarction prevention (BIP) study. J Clin Epidemiol 1995; 48: 757-765.
59. Goldbourt U, Behar S, Reicherreiss H et al. Rationale and design of a secondary prevention trial ofcreasing serum high-density-lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart-disease (the bezafibrate infarction prevention trial). Am J Cardiol 1993; 71: 909-915.
60. Kaplinsky E. Results of the Bezafibrate Infarction Prevention Study (BIP). 1998. Presented at the annual meeting of the European Society of Cardiology, Vienna, Austria, 22-26 August 1998.
61. Davenport J, Babikian V, Brass LM, Collins D, Robins S, Rubins H. Stroke events in the Veterans Affairs HDL Intervention Trial (VA-HIT). Ann Neurol 1998; 44: T109.
62. Davenport J. Presentation at a satellite symposium of the 71st Scientific Session of the American Heart Association, Dallas, Texas. 8 November 1998.
63. Feher MD, Elkeles RS. Lipid modification and coronary heart disease in type 2 diabetes: different from the general population? Heart 1998; 81: 10-11.
64. Diabetes Control, Complications Trial Research Group. The effect offensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986.
65. Reichard P, Berglund B, Britz A, Cars I, Nilsson BY, Rosenqvist U. Intensified conventional insulin treatment retards the microvascular complications ofsulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intl Med 1991; 230: 101-108.
66. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvas-cular complications in Japanese patients with non insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
67. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
68. University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes VII: mortality and selected nonfatal events with insulin treatment. J Am Med Assoc 1978; 240: 37-42.
69. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
70. Hypertension in Diabetes Study Group. HDS 1: prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hyperten 1993; 11: 309-317.
71. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
72. Wood D, De Backer G, Faergemann O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the second joint Task Force of European and other Societies on Coronary Prevention. Eur Heart J 1998; 19: 1434-1503.
73. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl J Med 1996; 335: 1001-1009.